Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis

Hepatology

Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis

Lancet Gastroenterol Hepatol

Petroff D, Blank V, Newsome PN, Shalimar, Voican CS, Thiele M, de Lédinghen V, Baumeler S, Chan WK, Perlemuter G, Cardoso AC, Aggarwal S, Sasso M, Eddowes PJ, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Cobbold JF, Naveau S, Lupsor-Platon M, Mueller S, Krag A, Irles-Depe M, Semela D, Wong GL, Wong VW, Villela-Nogueira CA, Garg H, Chazouillères O, Wiegand J, Karlas T

doi: 10.1016/S2468-1253(20)30357-5

HepatitisHepatology

Prevalence of sero-markers and non-invasive assessment of liver cirrhosis in patients with Hepatitis B virus infection in Freetown, Sierra Leone: a cross-sectional study

BMC Gastroenterol

Lakoh S, Firima E, Jiba DF, Kamara MN, Gashau W, Deen GF, Adekanmbi O, Yendewa GA

doi: 10.1186/s12876-021-01892-5

Hepatology

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

Lancet Gastroenterol Hepatol.

Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, Yilmaz Y, Czernichow S, Zheng MH, Wong VW, Allison M, Tsochatzis E, Anstee QM, Sheridan DA, Eddowes PJ, Guha IN, Cobbold JF, Paradis V, Bedossa P, Miette V, Fournier-Poizat C, Sandrin L, Harrison SA

doi: 10.1016/S2468-1253(19)30383-8.

Hepatitis

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Lancet.

Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE

doi: 10.1016/S0140-6736(19)32517-6.

Hepatology

Alcohol Use is Associated with Hepatic Steatosis Among Persons with Presumed Non-alcoholic Fatty Liver Disease

Clin Gastroenterol Hepatol.

Long MT, Massaro JM, Hoffmann U, Benjamin EJ, Naimi TS

doi: 10.1016/j.cgh.2019.11.022.

Hepatology

Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease

J Hepatol

Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, Pennisi G, Liguori A, Francione P, Gallego-Durán R, Ampuero J, Garcia Blanco MJ, Aller R, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Pareja MJ, Zaki MYW, Grieco A, Fracanzani AL, Valenti L, Miele L, Fariselli P, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E

doi: 10.1016/j.jhep.2021.05.008

Gastroesophageal Reflux Disease (GERD)

Application of Lyon Consensus criteria for GORD diagnosis: evaluation of conventional and new impedance-pH parameters

Gut

Frazzoni L, Frazzoni M, De Bortoli N, Ribolsi M, Tolone S, Russo S, Conigliaro RL, Penagini R, Fuccio L, Zagari RM, Savarino E

doi: 10.1136/gutjnl-2021-325531

HepatitisHepatology

Non-Alcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B

Hepatology.

Choi HSJ, Brouwer WP, Zanjir WMR, de Man RA, Feld JJ, Hansen BE, Janssen HLA, Patel K

doi: 10.1002/hep.30857.

Hepatitis

Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)

Gut.

Liem KS, Fung S, Wong DK, Yim C, Noureldin S, Chen J, Feld JJ, Hansen BE, Janssen HLA

doi: 10.1136/gutjnl-2019-318981.

Related content

Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis

Prevalence of sero-markers and non-invasive assessment of liver cirrhosis in patients with Hepatitis B virus infection in Freetown, Sierra Leone: a cross-sectional study

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Alcohol Use is Associated with Hepatic Steatosis Among Persons with Presumed Non-alcoholic Fatty Liver Disease

Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease

Application of Lyon Consensus criteria for GORD diagnosis: evaluation of conventional and new impedance-pH parameters

Non-Alcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B

Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)